What diseases does Vanzacato/Tizakattor/Deuterated Ivacaftor composite tablets mainly treat? Who is it suitable for?

This composite tablet is mainly used to treat cystic fibrosis (Cystic Fibrosis, CF). It is a targeted drug for patients with CFTR gene mutations. Among them, vanzaccator and tizaccator are CFTR protein regulators that can repair protein folding and transport functions; deuterated ivacaftor is the deuterated version of ivacaftor, which prolongs the metabolism time and improves drug efficacy. This drug is suitable for patients who carry at least one F508del mutation. It can significantly improve lung function, reduce sputum viscosity, and reduce the incidence of lung infection. Compared with traditional treatment, this type of triple compound tablets improves CFTR function from the cause and brings more lasting and stable clinical effects, especially suitable for patients with moderate to severe CF.